Groupe BPCE
Close the search form

Natixis renews its commitment to the Gustave Roussy Foundation to fund cancer research

Three new research projects will be supported over three years.

Actively committed since 2011 to the fight against cancer alongside Gustave Roussy's researchers, Natixis has renewed its sponsorship and is involved in a clinical trial in the area of precision medicine, the MATCH-R trial, led by Professor Jean-Charles Soria, Head of the Department of Therapeutic Innovation and Early Tests, and Professor Fabrice André, Director of the INSERM U981 unit.

The aim of this research is to understand how cancer cells adapt to targeted therapies and immunotherapies by developing resistance mechanisms. Natixis has also decided to support two new teams over 3 years. They work in fundamental research on the most promising topics in oncology: immunology and DNA repair. The two teams selected by Natixis are winners of the ATIP-Avenir program jointly organized by CNRS and Inserm. The objective of this program is to enable young high-level researchers to set up and lead a team.

  • Natixis